Meningococcal carriage, meningococcal disease and vaccination
- PMID: 3130424
- DOI: 10.1016/s0163-4453(88)96117-8
Meningococcal carriage, meningococcal disease and vaccination
Abstract
Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%). The carriage rate remained high during a second survey made 6 months after a vaccination campaign that covered approximately 90% of the study population. A year later very few group A meningococcal carriers were found. Membrane protein patterns of isolates obtained before and after vaccination were similar. We conclude that vaccination had little influence on the carriage rate of group A meningococci but that this was influenced by changes in herd immunity or by other unidentified factors.
Similar articles
-
SDS-PAGE analysis of membrane proteins of group A Neisseria meningitidis isolated before and during an epidemic of group A meningococcal disease in northern Nigeria.Trans R Soc Trop Med Hyg. 1987;81(1):11-3. doi: 10.1016/0035-9203(87)90269-0. Trans R Soc Trop Med Hyg. 1987. PMID: 3127952
-
Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine.J Infect. 1988 Sep;17(2):177-82. doi: 10.1016/s0163-4453(88)91907-x. J Infect. 1988. PMID: 3141518
-
Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates.J Infect. 1981 Sep;3(3):266-72. doi: 10.1016/s0163-4453(81)90934-8. J Infect. 1981. PMID: 6821094 Clinical Trial. No abstract available.
-
Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.Expert Rev Anti Infect Ther. 2011 Sep;9(9):761-74. doi: 10.1586/eri.11.89. Expert Rev Anti Infect Ther. 2011. PMID: 21905785 Review.
-
Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis.Epidemiol Infect. 2019 Jan;147:e228. doi: 10.1017/S0950268819001134. Epidemiol Infect. 2019. PMID: 31364554 Free PMC article.
Cited by
-
Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.Med Decis Making. 2019 Jul;39(5):553-567. doi: 10.1177/0272989X19859899. Epub 2019 Jul 3. Med Decis Making. 2019. PMID: 31268405 Free PMC article.
-
Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.Eur J Pediatr. 2013 May;172(5):601-12. doi: 10.1007/s00431-012-1924-0. Epub 2013 Jan 11. Eur J Pediatr. 2013. PMID: 23307281 Free PMC article. Clinical Trial.
-
Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.Pathog Glob Health. 2017 Feb;111(1):1-6. doi: 10.1080/20477724.2016.1274068. Epub 2017 Jan 12. Pathog Glob Health. 2017. PMID: 28081671 Free PMC article. Review.
-
Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse.Epidemiol Infect. 1989 Apr;102(2):271-80. doi: 10.1017/s0950268800029940. Epidemiol Infect. 1989. PMID: 2703020 Free PMC article.
-
Meningococcal conjugate vaccines: optimizing global impact.Infect Drug Resist. 2011;4:161-9. doi: 10.2147/IDR.S21545. Epub 2011 Sep 21. Infect Drug Resist. 2011. PMID: 22114508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical